Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710839 · ClinicalTrials.gov registry record · Phase 4
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
A Phase 4 study, sponsored by Charles C Wykoff, PhD, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT01710839: Completed Phase 4 study, sponsored by Charles C Wykoff, PhD, MD.
NCT01710839 is a Phase 4 study that has completed, run by Charles C Wykoff, PhD, MD. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01710839, a Phase 4 study, has completed, sponsored by Charles C Wykoff, PhD, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch retinal vein occlusions compared to standard of care
Primary Outcome
Assess the number of intravitreal injections over 12 months.
Interventions
- PROCEDURE Targeted Pan Retinal Photocoagulation
- DRUG 0.5mg Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
What the finished NCT01710839 record still lists
NCT01710839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Targeted Pan Retinal Photocoagulation is the first listed.
NCT01710839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01710839 about?
NCT01710839 is a clinical study titled "Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion". To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch retinal vein occlusions compared to standard of care
What is the current status of trial NCT01710839?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2012-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01710839?
The interventions under investigation include: Targeted Pan Retinal Photocoagulation (PROCEDURE), 0.5mg Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01710839?
This trial is sponsored by Charles C Wykoff, PhD, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01710839's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia